Catalyst Pharmaceuticals, Inc.
CPRX
$31.16
$0.020.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.11% | 2.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.11% | 2.84% | |||
| Cost of Revenue | -38.54% | 10.15% | |||
| Gross Profit | 6.03% | 1.34% | |||
| SG&A Expenses | -7.68% | 12.54% | |||
| Depreciation & Amortization | 2.51% | 1.29% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.10% | 10.52% | |||
| Operating Income | 18.41% | -6.67% | |||
| Income Before Tax | 17.15% | 1.22% | |||
| Income Tax Expenses | 6.73% | 5.21% | |||
| Earnings from Continuing Operations | 20.94% | -0.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.94% | -0.16% | |||
| EBIT | 18.41% | -6.67% | |||
| EBITDA | 16.28% | -5.68% | |||
| EPS Basic | 21.57% | -0.39% | |||
| Normalized Basic EPS | 16.59% | -6.52% | |||
| EPS Diluted | 21.95% | -2.38% | |||
| Normalized Diluted EPS | 16.45% | -6.54% | |||
| Average Basic Shares Outstanding | -0.53% | 0.25% | |||
| Average Diluted Shares Outstanding | -0.41% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||